Acceleron Pharma Inc. (XLRN) Receives $42.00 Average Price Target from Analysts

Acceleron Pharma Inc. (NASDAQ:XLRN) has been given an average rating of “Buy” by the eighteen analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $42.17.

A number of analysts have issued reports on XLRN shares. Credit Suisse Group reaffirmed an “outperform” rating and issued a $46.00 price objective on shares of Acceleron Pharma in a research note on Tuesday, April 18th. JMP Securities reiterated an “outperform” rating and issued a $39.00 target price on shares of Acceleron Pharma in a report on Monday, May 1st. Zacks Investment Research cut Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Goldman Sachs Group, Inc. (The) assumed coverage on Acceleron Pharma in a research note on Wednesday, May 17th. They set a “sell” rating and a $20.00 price objective for the company. Finally, FBR & Co reaffirmed a “buy” rating on shares of Acceleron Pharma in a research report on Thursday, May 18th.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded up 2.93% during trading on Friday, hitting $34.04. 216,645 shares of the stock were exchanged. The firm has a 50 day moving average price of $32.32 and a 200 day moving average price of $28.82. Acceleron Pharma has a 52 week low of $23.07 and a 52 week high of $41.69. The firm’s market capitalization is $1.32 billion.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.12. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.69 million. During the same period in the prior year, the firm posted ($0.59) earnings per share. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. Analysts forecast that Acceleron Pharma will post ($2.73) EPS for the current fiscal year.

In other news, CFO Kevin F. Mclaughlin sold 34,400 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $1,100,800.00. Following the completion of the sale, the chief financial officer now directly owns 80,950 shares of the company’s stock, valued at approximately $2,590,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Ravindra Kumar sold 13,065 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $35.41, for a total value of $462,631.65. Following the completion of the transaction, the senior vice president now owns 108,392 shares in the company, valued at approximately $3,838,160.72. The disclosure for this sale can be found here. Insiders have sold a total of 64,402 shares of company stock valued at $2,105,416 over the last ninety days. 3.90% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Acceleron Pharma by 4,559.6% in the first quarter. BlackRock Inc. now owns 3,674,593 shares of the biopharmaceutical company’s stock worth $97,266,000 after buying an additional 3,595,733 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Acceleron Pharma by 46.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock worth $51,127,000 after buying an additional 534,440 shares in the last quarter. AXA purchased a new stake in Acceleron Pharma during the second quarter worth $9,833,000. Norges Bank purchased a new stake in Acceleron Pharma during the fourth quarter worth $8,234,000. Finally, UBS Asset Management Americas Inc. purchased a new stake in Acceleron Pharma during the second quarter worth $9,747,000. Institutional investors and hedge funds own 83.65% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/brokerages-set-acceleron-pharma-inc-xlrn-pt-at-42-00-updated-updated.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

What are top analysts saying about Acceleron Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit